The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | MANIFEST: pelabresib (CPI-0610) + ruxolitinib in advanced myelofibrosis patients
Srdan Verstovsek, MD, PhD, of the University of Texas MD Anderson Cancer Center, Houston, TX, updates us on the Phase II MANIFEST study (NCT02158858), evaluating the addition of pelabresib (CPI-0610), a bromodomain and extraterminal domain protein inhibitor, to ruxolitinib in advanced myelofibrosis patients with suboptimal responses. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
